A commonly accepted standard protocol for noninvasive techniques for the genetic evaluation of an embryo remains elusive due to inconclusiveness regarding the volume of spent media to be acquired and the possibility of acquiring the same for subsequent analysis. Single embryo culture is imperative for standardizing noninvasive preimplantation testing using cell-free DNA (cf-DNA) released by individual developing embryos. This study aims to compare the development dynamics of single-drop embryonic culture against with group embryonic culture to establish a standardized protocol for noninvasive Preimplantation Genetic Testing (PGT) in bovine. A total of 239 cumulus-oocyte complexes were aspirated and subjected to in vitro maturation and fertilization. Among these, 120 embryos of day 3 were transferred to single-drop culture until the blastocyst stage. The single-drop culture drops were prepared using microdrops of 30 μL. At the blastocyst stage, spent media from all single-drop embryos were utilized for extracting cell-free genomic DNA to standardize the protocol. The blastocyst rate indicates no significant difference between the two culture methods, suggesting that single-drop culture is suitable for the process. Additionally, the extracted spent media yielded sufficient quantities of cf-DNA, supporting its potential use for PGT ( p < 0.05). These findings support the hypothesis that single-drop embryo culture is a viable method for cf-DNA extraction and confirm the potential of using DNA fragments from spent media as a reliable source for noninvasive PGT.
{"title":"Analyzing Cell-free Genomic DNA in Spent Culture Media: Noninvasive Insight into the Blastocysts.","authors":"Siddhartha Shankar Layek, Shrushti Kanani, Shilpa Doultani, Tejas Gohil, Sanket Patil, Ananthasayanam Sudhakar, Kathan Banubhai Raval, Karuppanasamy Kuppusamy, Sanjay Gorani, Sudharson Raj, Rafiya Sangameshwari, Himali Jadeja, Mini Mol P","doi":"10.1055/s-0044-1788260","DOIUrl":"10.1055/s-0044-1788260","url":null,"abstract":"<p><p>A commonly accepted standard protocol for noninvasive techniques for the genetic evaluation of an embryo remains elusive due to inconclusiveness regarding the volume of spent media to be acquired and the possibility of acquiring the same for subsequent analysis. Single embryo culture is imperative for standardizing noninvasive preimplantation testing using cell-free DNA (cf-DNA) released by individual developing embryos. This study aims to compare the development dynamics of single-drop embryonic culture against with group embryonic culture to establish a standardized protocol for noninvasive Preimplantation Genetic Testing (PGT) in bovine. A total of 239 cumulus-oocyte complexes were aspirated and subjected to in vitro maturation and fertilization. Among these, 120 embryos of day 3 were transferred to single-drop culture until the blastocyst stage. The single-drop culture drops were prepared using microdrops of 30 μL. At the blastocyst stage, spent media from all single-drop embryos were utilized for extracting cell-free genomic DNA to standardize the protocol. The blastocyst rate indicates no significant difference between the two culture methods, suggesting that single-drop culture is suitable for the process. Additionally, the extracted spent media yielded sufficient quantities of cf-DNA, supporting its potential use for PGT ( <i>p</i> < 0.05). These findings support the hypothesis that single-drop embryo culture is a viable method for cf-DNA extraction and confirm the potential of using DNA fragments from spent media as a reliable source for noninvasive PGT.</p>","PeriodicalId":40142,"journal":{"name":"Global Medical Genetics","volume":"11 3","pages":"227-232"},"PeriodicalIF":1.5,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11265834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141752979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-22eCollection Date: 2024-09-01DOI: 10.1055/s-0044-1788614
Ivan Milas, Željko Kaštelan, Jószef Petrik, Jasna Bingulac-Popović, Bojan Čikić, Andrej Šribar, Irena Jukić
Background Previous research on connection between the ABO blood group and bladder cancer has been based on determining the ABO phenotype. This specific research is extended to the molecular level, providing more information about particular ABO alleles. Aim To investigate the impact of the ABO blood group genotype or phenotype as a risk factor for urinary bladder cancer. Materials and Methods In the case-control study, we included 74 patients who underwent surgery for a urinary bladder tumor at the Urology Clinic, Clinical Hospital Centre Zagreb, in 2021 and 2022. The control group comprised 142 asymptomatic and healthy blood donors. ABO genotyping to five basic alleles was done using a polymerase chain reaction with sequence-specific primers. We compared ABO phenotypes, genotypes, and alleles between patients and the healthy controls and investigated their distribution according to the clinical and histological stage and recurrence rate. Results No statistically significant difference was found among the groups, nor for the observed disease stages in terms of the phenotype and genotype. At the allele level, the results show a significantly lower proportion of malignancy in O1 ( p < 0.001), A1 ( p < 0.001), and B ( p = 0.013), and a lower proportion of metastatic disease in A2 (0%, p = 0.024). We also found significantly higher proportions of high-grade tumors in patients with O1 (71.4%, p < 0.001), A1 (70.1%, p = 0.019), of nonmuscle invasive tumors in patients with O1 (55.1%, p < 0.001), O2 (100%, p = 0.045), and recurrent tumors in patients with O1 (70.2%, p < 0.001) and A1 (74.2%, p = 0.007) alleles. Conclusion We did not find an association between the ABO blood group genotype or phenotype as a genetic risk factor for urinary bladder cancer. However, an analysis at the allelic level revealed a statistically significant association between certain alleles of the ABO blood group system and urinary bladder tumors, clinical or histological stage, and recurrence rate, respectively.
{"title":"ABO Blood Type and Urinary Bladder Cancer: Phenotype, Genotype, Allelic Association with a Clinical or Histological Stage and Recurrence Rate.","authors":"Ivan Milas, Željko Kaštelan, Jószef Petrik, Jasna Bingulac-Popović, Bojan Čikić, Andrej Šribar, Irena Jukić","doi":"10.1055/s-0044-1788614","DOIUrl":"10.1055/s-0044-1788614","url":null,"abstract":"<p><p><b>Background</b> Previous research on connection between the ABO blood group and bladder cancer has been based on determining the ABO phenotype. This specific research is extended to the molecular level, providing more information about particular ABO alleles. <b>Aim</b> To investigate the impact of the ABO blood group genotype or phenotype as a risk factor for urinary bladder cancer. <b>Materials and Methods</b> In the case-control study, we included 74 patients who underwent surgery for a urinary bladder tumor at the Urology Clinic, Clinical Hospital Centre Zagreb, in 2021 and 2022. The control group comprised 142 asymptomatic and healthy blood donors. ABO genotyping to five basic alleles was done using a polymerase chain reaction with sequence-specific primers. We compared ABO phenotypes, genotypes, and alleles between patients and the healthy controls and investigated their distribution according to the clinical and histological stage and recurrence rate. <b>Results</b> No statistically significant difference was found among the groups, nor for the observed disease stages in terms of the phenotype and genotype. At the allele level, the results show a significantly lower proportion of malignancy in O1 ( <i>p</i> < 0.001), A1 ( <i>p</i> < 0.001), and B ( <i>p</i> = 0.013), and a lower proportion of metastatic disease in A2 (0%, <i>p</i> = 0.024). We also found significantly higher proportions of high-grade tumors in patients with O1 (71.4%, <i>p</i> < 0.001), A1 (70.1%, <i>p</i> = 0.019), of nonmuscle invasive tumors in patients with O1 (55.1%, <i>p</i> < 0.001), O2 (100%, <i>p</i> = 0.045), and recurrent tumors in patients with O1 (70.2%, <i>p</i> < 0.001) and A1 (74.2%, <i>p</i> = 0.007) alleles. <b>Conclusion</b> We did not find an association between the ABO blood group genotype or phenotype as a genetic risk factor for urinary bladder cancer. However, an analysis at the allelic level revealed a statistically significant association between certain alleles of the ABO blood group system and urinary bladder tumors, clinical or histological stage, and recurrence rate, respectively.</p>","PeriodicalId":40142,"journal":{"name":"Global Medical Genetics","volume":"11 3","pages":"233-240"},"PeriodicalIF":1.5,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11262885/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141749257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-12eCollection Date: 2024-09-01DOI: 10.1055/s-0044-1788572
Xiaochen Wang, Lijun Liu
{"title":"Bridging Innovation Research with Clinical Application: Clinical Trials at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences.","authors":"Xiaochen Wang, Lijun Liu","doi":"10.1055/s-0044-1788572","DOIUrl":"10.1055/s-0044-1788572","url":null,"abstract":"","PeriodicalId":40142,"journal":{"name":"Global Medical Genetics","volume":"11 3","pages":"225-226"},"PeriodicalIF":1.5,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11245325/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141617358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-09eCollection Date: 2024-09-01DOI: 10.1055/s-0044-1788060
Francesca Peranzoni, Roberto De Castro, Emilio Merlini, Yen Le Nguyen
True hermaphroditism is a disorder of sex development (DSD), accounting for less than 5% of all DSD cases, defined by the simultaneous presence of testicular tissue and ovarian tissue in the same individual. In the reported case, the patient presented two genetic mutations involved in the pathogenic pathway of the DSD condition associated with the clinical features of Kallmann syndrome (KS), a developmental disease that associates hypogonadotropic hypogonadism (HH), due to gonadotropin-releasing hormone deficiency, and anosmia, related to the absence or hypoplasia of the olfactory bulbs. Given the variable degree of hyposmia in KS, the distinction between KS and normosmic idiopathic HH is currently unclear, especially as HH patients do not always undergo detailed olfactory testing. This syndrome is very rare, with an estimated prevalence of 1:80,000 in males and 1:40,000 in females. This is the only case report concerning a patient with 46 XX true hermaphroditism affected by HH and digenic inheritance of Kallmann syndrome.
{"title":"46 XX Ovotesticular Disorder of Sex Development with Gonadotropin-Releasing Hormone Receptor, Autosomal Recessive Heterozygous Missense Mutation and Autosomal Dominant Heterozygous Missense Mutation of the <i>PROKR2</i> Gene: A Case Report.","authors":"Francesca Peranzoni, Roberto De Castro, Emilio Merlini, Yen Le Nguyen","doi":"10.1055/s-0044-1788060","DOIUrl":"10.1055/s-0044-1788060","url":null,"abstract":"<p><p>True hermaphroditism is a disorder of sex development (DSD), accounting for less than 5% of all DSD cases, defined by the simultaneous presence of testicular tissue and ovarian tissue in the same individual. In the reported case, the patient presented two genetic mutations involved in the pathogenic pathway of the DSD condition associated with the clinical features of Kallmann syndrome (KS), a developmental disease that associates hypogonadotropic hypogonadism (HH), due to gonadotropin-releasing hormone deficiency, and anosmia, related to the absence or hypoplasia of the olfactory bulbs. Given the variable degree of hyposmia in KS, the distinction between KS and normosmic idiopathic HH is currently unclear, especially as HH patients do not always undergo detailed olfactory testing. This syndrome is very rare, with an estimated prevalence of 1:80,000 in males and 1:40,000 in females. This is the only case report concerning a patient with 46 XX true hermaphroditism affected by HH and digenic inheritance of Kallmann syndrome.</p>","PeriodicalId":40142,"journal":{"name":"Global Medical Genetics","volume":"11 3","pages":"220-224"},"PeriodicalIF":1.5,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11233268/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141581079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-05eCollection Date: 2024-09-01DOI: 10.1055/s-0044-1788043
Shiyuan Wang, Jun Li, Ying Li, Xiaoming Liu, Lixian Chang, Beibei Zhao, Li Zhang, Yao Zou, Min Ruan, Xiaofan Zhu
Cerebral venous sinus thrombosis (CVST) and hyperlipidemia are severe complications of L-Asparaginase (L-Asp) during the treatment of B-cell acute lymphoblastic leukemia (B-ALL). Herein, we reported a 9-year-old B-ALL boy who underwent abnormal hypertriglyceridemia and CVST presenting as seizures and disturbance of consciousness twice during the induction therapy. Fortunately, he survived treatment with anticoagulant and lipid-lowering therapy. No thrombophilia-related gene mutation was detected, but a heterozygous mutation in lipoprotein lipase (LPL) gene was identified. His neurological symptoms were managed with short-term anticoagulant therapy and long-term lipid-lowering therapy. This case illustrated the manifestation and potential pathogenesis of CVST and highlighted the essentiality of screening baseline lipid profile and dyslipidemia- and thrombophilia-related gene mutation.
脑静脉窦血栓(CVST)和高脂血症是天冬酰胺酶(L-Asp)治疗 B 细胞急性淋巴细胞白血病(B-ALL)期间的严重并发症。在此,我们报告了一名 9 岁的 B-ALL 男孩,他在诱导治疗期间两次出现异常的高甘油三酯血症和 CVST,表现为癫痫发作和意识障碍。幸运的是,他在接受抗凝和降脂治疗后存活了下来。虽然没有检测到血栓相关基因突变,但发现了脂蛋白脂肪酶(LPL)基因的杂合突变。他的神经症状通过短期抗凝治疗和长期降脂治疗得到了控制。该病例说明了 CVST 的表现和潜在发病机制,并强调了筛查基线血脂谱和血脂异常及血栓相关基因突变的重要性。
{"title":"Recurrent Cerebral Venous Sinus Thrombosis Occurred in an Acute Lymphoblastic Leukemia Child with Mutated Lipoprotein Lipase Gene during Asparaginase Therapy.","authors":"Shiyuan Wang, Jun Li, Ying Li, Xiaoming Liu, Lixian Chang, Beibei Zhao, Li Zhang, Yao Zou, Min Ruan, Xiaofan Zhu","doi":"10.1055/s-0044-1788043","DOIUrl":"10.1055/s-0044-1788043","url":null,"abstract":"<p><p>Cerebral venous sinus thrombosis (CVST) and hyperlipidemia are severe complications of L-Asparaginase (L-Asp) during the treatment of B-cell acute lymphoblastic leukemia (B-ALL). Herein, we reported a 9-year-old B-ALL boy who underwent abnormal hypertriglyceridemia and CVST presenting as seizures and disturbance of consciousness twice during the induction therapy. Fortunately, he survived treatment with anticoagulant and lipid-lowering therapy. No thrombophilia-related gene mutation was detected, but a heterozygous mutation in lipoprotein lipase (LPL) gene was identified. His neurological symptoms were managed with short-term anticoagulant therapy and long-term lipid-lowering therapy. This case illustrated the manifestation and potential pathogenesis of CVST and highlighted the essentiality of screening baseline lipid profile and dyslipidemia- and thrombophilia-related gene mutation.</p>","PeriodicalId":40142,"journal":{"name":"Global Medical Genetics","volume":"11 3","pages":"214-219"},"PeriodicalIF":1.5,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11226343/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141555651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-28eCollection Date: 2024-09-01DOI: 10.1055/s-0044-1788039
Zhiwei Zhang, Zhao Lei
Avian influenza viruses (AIVs) have the potential to cause severe illness in wild birds, domestic poultry, and humans. The ongoing circulation of highly pathogenic avian influenza viruses (HPAIVs) has presented significant challenges to global poultry industry and public health in recent years. This study aimed to elucidate the circulation of HPAIVs during 2019 to 2023. Specifically, we assess the alarming global spread and continuous evolution of HPAIVs. Moreover, we discuss their transmission and prevention strategies to provide valuable references for future prevention and control measures against AIVs.
{"title":"The Alarming Situation of Highly Pathogenic Avian Influenza Viruses in 2019-2023.","authors":"Zhiwei Zhang, Zhao Lei","doi":"10.1055/s-0044-1788039","DOIUrl":"10.1055/s-0044-1788039","url":null,"abstract":"<p><p>Avian influenza viruses (AIVs) have the potential to cause severe illness in wild birds, domestic poultry, and humans. The ongoing circulation of highly pathogenic avian influenza viruses (HPAIVs) has presented significant challenges to global poultry industry and public health in recent years. This study aimed to elucidate the circulation of HPAIVs during 2019 to 2023. Specifically, we assess the alarming global spread and continuous evolution of HPAIVs. Moreover, we discuss their transmission and prevention strategies to provide valuable references for future prevention and control measures against AIVs.</p>","PeriodicalId":40142,"journal":{"name":"Global Medical Genetics","volume":"11 3","pages":"200-213"},"PeriodicalIF":1.5,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11213626/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141471428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-13eCollection Date: 2024-06-01DOI: 10.1055/s-0044-1787301
Wenchao Xia, Jing Yang, Hongbin Li, Ling Li, Jinfeng Liu
Background Anaplastic lymphoma kinase ( ALK ) fusion events account for 3 to 7% of genetic alterations in patients with nonsmall cell lung cancer (NSCLC). This study aimed to explore the landscape of ALK fusion-positive and ALK fusion-negative in a large cohort of NSCLC patients. Methods The formalin-fixed paraffin-embedded specimens of NSCLC patients who underwent next-generation sequencing from 2020 to 2023 in Yinfeng Gene Technology Co., Ltd. Clinical laboratory were included in this study. Results In the current study, a total of 180 (3.20%) patients tested positive for ALK fusions in 5,622 NSCLC samples. Within the ALK -positive cohort, a total of 228 ALK fusions were identified. Furthermore, five novel ALK fusion partners, including DAB1-ALK , KCMF1-ALK , KIF13A-ALK , LOC643770-ALK , and XDH-ALK were identified. In cases with ALK fusion-positive, TP53 alterations were the most prevalent (26.3%), followed by CDKN2A (8.4%), epidermal growth factor receptor ( EGFR , 5.6%), and ALK (5.6%). By contrast, EGFR alterations were most prevalent (51%) in patients with ALK fusion-negative NSCLC, followed by TP53 (42.7%), KRAS (11.6%), and CDKN2A (11.3%). A total of 10 cases where ALK fusion co-occurred with EGFR mutations were also identified. Notably, the ALK fusion positivity rate was higher in younger patients ( p < 0.0001) and in female patients ( p = 0.0429). Additionally, positive ALK test results were more prevalent in patients with high programmed death-ligand 1 expression, especially when applying a 50% cutoff. Conclusions Collectively, these findings offer valuable genomic insights that could inform the personalized clinical care of patients with NSCLC harboring ALK fusions within the context of precision medicine.
{"title":"Comparing Genomic Profiles of <i>ALK</i> Fusion-Positive and <i>ALK</i> Fusion-Negative Nonsmall Cell Lung Cancer Patients.","authors":"Wenchao Xia, Jing Yang, Hongbin Li, Ling Li, Jinfeng Liu","doi":"10.1055/s-0044-1787301","DOIUrl":"10.1055/s-0044-1787301","url":null,"abstract":"<p><p><b>Background</b> Anaplastic lymphoma kinase ( <i>ALK</i> ) fusion events account for 3 to 7% of genetic alterations in patients with nonsmall cell lung cancer (NSCLC). This study aimed to explore the landscape of <i>ALK</i> fusion-positive and <i>ALK</i> fusion-negative in a large cohort of NSCLC patients. <b>Methods</b> The formalin-fixed paraffin-embedded specimens of NSCLC patients who underwent next-generation sequencing from 2020 to 2023 in Yinfeng Gene Technology Co., Ltd. Clinical laboratory were included in this study. <b>Results</b> In the current study, a total of 180 (3.20%) patients tested positive for <i>ALK</i> fusions in 5,622 NSCLC samples. Within the <i>ALK</i> -positive cohort, a total of 228 <i>ALK</i> fusions were identified. Furthermore, five novel <i>ALK</i> fusion partners, including <i>DAB1-ALK</i> , <i>KCMF1-ALK</i> , <i>KIF13A-ALK</i> , <i>LOC643770-ALK</i> , and <i>XDH-ALK</i> were identified. In cases with <i>ALK</i> fusion-positive, <i>TP53</i> alterations were the most prevalent (26.3%), followed by <i>CDKN2A</i> (8.4%), epidermal growth factor receptor ( <i>EGFR</i> , 5.6%), and <i>ALK</i> (5.6%). By contrast, <i>EGFR</i> alterations were most prevalent (51%) in patients with <i>ALK</i> fusion-negative NSCLC, followed by <i>TP53</i> (42.7%), <i>KRAS</i> (11.6%), and <i>CDKN2A</i> (11.3%). A total of 10 cases where <i>ALK</i> fusion co-occurred with <i>EGFR</i> mutations were also identified. Notably, the <i>ALK</i> fusion positivity rate was higher in younger patients ( <i>p</i> < 0.0001) and in female patients ( <i>p</i> = 0.0429). Additionally, positive <i>ALK</i> test results were more prevalent in patients with high programmed death-ligand 1 expression, especially when applying a 50% cutoff. <b>Conclusions</b> Collectively, these findings offer valuable genomic insights that could inform the personalized clinical care of patients with NSCLC harboring <i>ALK</i> fusions within the context of precision medicine.</p>","PeriodicalId":40142,"journal":{"name":"Global Medical Genetics","volume":"11 2","pages":"175-186"},"PeriodicalIF":1.5,"publicationDate":"2024-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11175831/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141318545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-10eCollection Date: 2024-06-01DOI: 10.1055/s-0044-1787752
Fangxiu Luo, Jialu Zhao, Yubao Chen, Zhenping Peng, Ran An, Yeling Lu, Jiaming Li
Objective Myelodysplastic syndrome (MDS) is a malignant clonal disorder of hematopoietic stem cells which is characterized by morphologic dysplasia. However, the pathological characteristics of megakaryocytes (MKs) in MDS patients with gene mutation are not well established. Methods Bone marrow MK specimens from 104 patients with primary MDS were evaluated, and all patients were distributed into two groups according to gene mutation associated with functional MKs. The morphologic and cellular characteristics of MKs and platelets were recorded and compared. Results The more frequently mutated genes in MDS patients were TUBB1 (11.54%), VWF (8.65%), NBEAL2 (5.77%), and the most common point mutation was TUBB1 p.(R307H) and p.(Q43P). Patients with MK mutation showed a decrease in adenosine diphosphate-induced platelet aggregation, high proportion of CD34 + CD61 + MKs (10.00 vs. 4.00%, p = 0.012), and short overall survival (33.15 vs. 40.50 months, p = 0.013). Further, patients with a higher percent of CD34 + CD61 + MKs (≧20.00%) had lower platelet counts (36.00 × 10 9 /L vs. 88.50 × 10 9 /L, p = 0.015) and more profound emperipolesis ( p = 0.001). By analyzing RNA-sequencing of MKs, differentially expressed mRNA was involved in physiological processes including platelet function and platelet activation, especially for MDS patients with high percent of CD34 + CD61 + MKs. The high levels of expression of CD62P, CXCL10, and S100A9 mRNA, shown by RNA sequencing, were validated by PCR assay. Conclusion High proportion of CD34 + CD61 + MKs was a poor prognostic factor in MDS patients with MK mutation. CD62P, CXCL10, and S100A9 may be the potential targets to evaluate the molecular link between gene defects and platelet function.
{"title":"Clinical and Molecular Characteristics of Megakaryocytes in Myelodysplastic Syndrome.","authors":"Fangxiu Luo, Jialu Zhao, Yubao Chen, Zhenping Peng, Ran An, Yeling Lu, Jiaming Li","doi":"10.1055/s-0044-1787752","DOIUrl":"10.1055/s-0044-1787752","url":null,"abstract":"<p><p><b>Objective</b> Myelodysplastic syndrome (MDS) is a malignant clonal disorder of hematopoietic stem cells which is characterized by morphologic dysplasia. However, the pathological characteristics of megakaryocytes (MKs) in MDS patients with gene mutation are not well established. <b>Methods</b> Bone marrow MK specimens from 104 patients with primary MDS were evaluated, and all patients were distributed into two groups according to gene mutation associated with functional MKs. The morphologic and cellular characteristics of MKs and platelets were recorded and compared. <b>Results</b> The more frequently mutated genes in MDS patients were <i>TUBB1</i> (11.54%), <i>VWF</i> (8.65%), <i>NBEAL2</i> (5.77%), and the most common point mutation was <i>TUBB1</i> p.(R307H) and p.(Q43P). Patients with MK mutation showed a decrease in adenosine diphosphate-induced platelet aggregation, high proportion of CD34 <sup>+</sup> CD61 <sup>+</sup> MKs (10.00 vs. 4.00%, <i>p</i> = 0.012), and short overall survival (33.15 vs. 40.50 months, <i>p</i> = 0.013). Further, patients with a higher percent of CD34 <sup>+</sup> CD61 <sup>+</sup> MKs (≧20.00%) had lower platelet counts (36.00 × 10 <sup>9</sup> /L vs. 88.50 × 10 <sup>9</sup> /L, <i>p</i> = 0.015) and more profound emperipolesis ( <i>p</i> = 0.001). By analyzing RNA-sequencing of MKs, differentially expressed mRNA was involved in physiological processes including platelet function and platelet activation, especially for MDS patients with high percent of CD34 <sup>+</sup> CD61 <sup>+</sup> MKs. The high levels of expression of CD62P, CXCL10, and S100A9 mRNA, shown by RNA sequencing, were validated by PCR assay. <b>Conclusion</b> High proportion of CD34 <sup>+</sup> CD61 <sup>+</sup> MKs was a poor prognostic factor in MDS patients with MK mutation. CD62P, CXCL10, and S100A9 may be the potential targets to evaluate the molecular link between gene defects and platelet function.</p>","PeriodicalId":40142,"journal":{"name":"Global Medical Genetics","volume":"11 2","pages":"187-195"},"PeriodicalIF":1.5,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11164576/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141301807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-10eCollection Date: 2024-06-01DOI: 10.1055/s-0044-1786815
Mainak Bardhan, Kiran Polavarapu, Dipti Baskar, Veeramani Preethish-Kumar, Seena Vengalil, Saraswati Nashi, Valakunja H Ganaraja, Dinesh Sharma, Karthik Kulanthaivelu, B N Nandeesh, Atchayaram Nalini
IntroductionVMA21 -related myopathy is one of the rare forms of slowly progressive myopathy observed in males. Till now, there have been only a handful of reports, mainly from Europe and America, and two reports from India. Method Here, we describe a case of genetically confirmed VMA21 -associated myopathy with clinical, histopathological, and imaging features with a list of known VMA21 mutations. Results A 29-year-old man had the onset of symptoms at 18 years of age with features of proximal lower limb weakness. Muscle magnetic resonance imaging showed the preferential involvement of vasti and adductor magnus. A biopsy of the left quadriceps femoris showed features of autophagic vacuolar myopathy with vacuoles containing granular eosinophilic materials. In targeted next-generation sequencing, hemizygous mutation in the 3' splice site of intron 2 of the VMA21 gene (c.164-7 T > A) was identified and confirmed the diagnosis of X-linked myopathy with excessive autophagy. Conclusion This report expands the phenotypic and genotypic profile of VMA21 -related myopathy, with a yet unreported mutation in India.
{"title":"Identification of a Novel Intronic Mutation in <i>VMA21</i> Associated with a Classical Form of X-Linked Myopathy with Autophagy.","authors":"Mainak Bardhan, Kiran Polavarapu, Dipti Baskar, Veeramani Preethish-Kumar, Seena Vengalil, Saraswati Nashi, Valakunja H Ganaraja, Dinesh Sharma, Karthik Kulanthaivelu, B N Nandeesh, Atchayaram Nalini","doi":"10.1055/s-0044-1786815","DOIUrl":"10.1055/s-0044-1786815","url":null,"abstract":"<p><p><b>Introduction</b> <i>VMA21</i> -related myopathy is one of the rare forms of slowly progressive myopathy observed in males. Till now, there have been only a handful of reports, mainly from Europe and America, and two reports from India. <b>Method</b> Here, we describe a case of genetically confirmed <i>VMA21</i> -associated myopathy with clinical, histopathological, and imaging features with a list of known VMA21 mutations. <b>Results</b> A 29-year-old man had the onset of symptoms at 18 years of age with features of proximal lower limb weakness. Muscle magnetic resonance imaging showed the preferential involvement of vasti and adductor magnus. A biopsy of the left quadriceps femoris showed features of autophagic vacuolar myopathy with vacuoles containing granular eosinophilic materials. In targeted next-generation sequencing, hemizygous mutation in the 3' splice site of intron 2 of the <i>VMA21</i> gene (c.164-7 T > A) was identified and confirmed the diagnosis of X-linked myopathy with excessive autophagy. <b>Conclusion</b> This report expands the phenotypic and genotypic profile of <i>VMA21</i> -related myopathy, with a yet unreported mutation in India.</p>","PeriodicalId":40142,"journal":{"name":"Global Medical Genetics","volume":"11 2","pages":"167-174"},"PeriodicalIF":1.5,"publicationDate":"2024-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11087142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140910875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}